about
Anti-cancer activity of a novel small molecule compound that simultaneously activates p53 and inhibits NF-κB signalingEpigenetic silencing of CXCL14 induced colorectal cancer migration and invasion.Involvement of NF-κB/IL-6 Pathway in the Processing of Colorectal Carcinogenesis in Colitis MiceLSF expression and its prognostic implication in colorectal cancerNimbolide, a limonoid triterpene, inhibits growth of human colorectal cancer xenografts by suppressing the proinflammatory microenvironmentAnimal models of colitis-associated carcinogenesis.Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice.Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds.The inhibitory effects of 5-hydroxy-3,6,7,8,3',4'-hexamethoxyflavone on human colon cancer cells.A novel statistical approach for identification of the master regulator transcription factor.Serum metabolomic profile as a means to distinguish stage of colorectal cancer.The pharmacological NF-κB inhibitor BAY11-7082 induces cell apoptosis and inhibits the migration of human uveal melanoma cellsThe oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma.Curcumin sensitizes human lung cancer cells to apoptosis and metastasis synergistically combined with carboplatin.Mertensene, a Halogenated Monoterpene, Induces G2/M Cell Cycle Arrest and Caspase Dependent Apoptosis of Human Colon Adenocarcinoma HT29 Cell Line through the Modulation of ERK-1/-2, AKT and NF-κB Signaling.A phosphomimetic mutant of RelA/p65 at Ser536 induces apoptosis and senescence: An implication for tumor-suppressive role of Ser536 phosphorylation.The Gβ5 protein regulates sensitivity to TRAIL-induced cell death in colon carcinoma.Self-renewal molecular mechanisms of colorectal cancer stem cells.The cytotoxic effects of regorafenib in combination with protein kinase D inhibition in human colorectal cancer cells.The ANK repeats of Notch-4/Int3 activate NF-κB canonical pathway in the absence of Rbpj and causes mammary tumorigenesis.A small molecule, (E)-2-methoxy-4-(3-(4-methoxyphenyl) prop-1-en-1-yl) phenol suppresses tumor growth via inhibition of IkappaB kinase β in colorectal cancer in vivo and in vitro.KRAS mutation and NF-κB activation indicates tolerance of chemotherapy and poor prognosis in colorectal cancer.Simultaneous targeting therapy for lung metastasis and breast tumor by blocking the NF-κB signaling pathway using Celastrol-loaded micelles.miR‑873 inhibits colorectal cancer cell proliferation by targeting TRAF5 and TAB1.Curcumin-enhanced chemosensitivity of FDA-approved platinum (II)-based anti-cancer drugs involves downregulation of nuclear endonuclease G and NF-κB as well as induction of apoptosis and G2/M arrest.Novel synthetic curcumin analogs as potent antiangiogenic agents in colorectal cancer.Enterococcus faecalis AHG0090 is a Genetically Tractable Bacterium and Produces a Secreted Peptidic Bioactive that Suppresses Nuclear Factor Kappa B Activation in Human Gut Epithelial Cells.Silencing NIK potentiates anti-VEGF therapy in a novel 3D model of colorectal cancer angiogenesis.
P2860
Q28483751-2BD8622E-9F87-4BAE-AEBF-53B4AD1458E7Q33771084-D81A0406-D4CC-43C6-9245-2EFC10433F59Q33908674-147C1B9E-21B7-4039-8370-C824C403D38DQ34371544-635BFDC8-9CCC-4EAF-9DB0-20B340A59AA7Q34455364-EAC36B5B-1336-4552-ADAA-4AB752109486Q34512820-A7F8E953-754A-407B-BCF8-2B4BD69A1AE4Q35091403-80EE26D8-0FE1-4D21-A155-22DEE5746158Q35624238-1F88DC93-3465-4F8C-B7C2-3D4AA7760A0CQ36254268-9DA92475-7517-421E-A4E9-9FC74DE1B45CQ36266718-B5546826-7396-46D3-8BD4-06C0BFC332CDQ36424746-A2ABEDF8-EDF8-4E8D-9DFA-A0E8376E6F0EQ36538277-E19BD4A8-385A-4F58-9660-927787882D01Q36738884-496CDB57-194F-433D-ADB9-1F0D59C99DF7Q38428287-26739F47-A156-41B6-AE93-5A67C0973A57Q38696774-73B96F58-C6C7-4CD9-AB0D-DB0829C787EFQ38834978-DBA497E9-C6F8-421C-8875-60E1C97CCD7AQ38973682-3FA6A3B0-CEED-4F21-AB7F-A316B4DBCAD9Q39026588-4AD89645-F055-4CAD-8F08-FDDB688B6866Q42434225-7EA92A42-5F3F-471D-BDE1-371D99AA4313Q42652857-DAC065F1-F2E9-4F02-BC1B-E57785F052F7Q47141753-4DA20BBA-6B12-4755-9517-1533698C0F1FQ47865836-961F0222-F555-41CD-BDF3-B08157F05759Q49887095-B9B342FF-A004-4008-95CE-DAF0C55211DFQ50067509-9CA34790-1D96-4482-A90F-18901B839D01Q53072271-43C6398D-29CF-40A8-9E3D-7ACEE092B68FQ53111716-C531E974-1CF1-40E5-8A42-93D3C1FF518DQ54940051-83255B07-9FFD-4567-83F9-135E7DBD6B7EQ55502779-8999126B-B103-4658-ACB8-CC7F92EAF5B7
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting NF-kappaB for colorectal cancer.
@en
Targeting NF-kappaB for colorectal cancer.
@nl
type
label
Targeting NF-kappaB for colorectal cancer.
@en
Targeting NF-kappaB for colorectal cancer.
@nl
prefLabel
Targeting NF-kappaB for colorectal cancer.
@en
Targeting NF-kappaB for colorectal cancer.
@nl
P2860
P1476
Targeting NF-kappaB for colorectal cancer.
@en
P2093
Kei Sakamoto
Shin Maeda
P2860
P304
P356
10.1517/14728221003769903
P407
P577
2010-06-01T00:00:00Z